MENU
+Compare
INKT
Stock ticker: NASDAQ
AS OF
Jun 5 closing price
Price
$7.29
Change
+$0.19 (+2.68%)
Capitalization
29.06M

INKT MiNK Therapeutics Inc Forecast, Technical & Fundamental Analysis

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases... Show more

INKT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for INKT with price predictions
Jun 05, 2025

INKT's Stochastic Oscillator sits in oversold zone for 5 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for INKT just turned positive on June 05, 2025. Looking at past instances where INKT's MACD turned positive, the stock continued to rise in of 37 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where INKT advanced for three days, in of 160 cases, the price rose further within the following month. The odds of a continued upward trend are .

INKT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on May 29, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on INKT as a result. In of 72 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The 50-day moving average for INKT moved below the 200-day moving average on June 02, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INKT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for INKT entered a downward trend on May 20, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. INKT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (16.332). P/E Ratio (0.000) is within average values for comparable stocks, (59.787). INKT's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.227). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (263.647).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INKT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
INKT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
149 Fifth Avenue
Phone
+1 212 994-8250
Employees
31
Web
https://www.minktherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ANNX2.540.11
+4.53%
Annexon
NGD4.900.21
+4.48%
New Gold
BIDU85.850.96
+1.13%
Baidu
VMI322.200.49
+0.15%
Valmont Industries
WWR0.51N/A
-0.49%
Westwater Resources

INKT and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, INKT has been loosely correlated with RAIN. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if INKT jumps, then RAIN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INKT
1D Price
Change %
INKT100%
+2.65%
RAIN - INKT
43%
Loosely correlated
+6.24%
LPTX - INKT
43%
Loosely correlated
-2.40%
ABCZF - INKT
33%
Loosely correlated
N/A
TERN - INKT
30%
Poorly correlated
+1.14%
ORMP - INKT
29%
Poorly correlated
-5.70%
More